Estudio de predisposición al cáncer infantil (CCPS) (CCPS)
The Childhood Cancer Predisposition Study (CCPS) is a multi-center, longitudinal, observational study that will collect clinical and biological data and specimens from children with a cancer predisposition syndromes (CPS) and their relatives.
The central hypothesis is that studying individuals at high risk for childhood cancer creates a unique opportunity for improving the understanding of carcinogenesis, tumor surveillance, early detection, and cancer prevention, which will collectively contribute to improving care and outcomes for pediatric patients with cancer and those with cancer predisposition syndromes (CPS).
Descripción general del estudio
Descripción detallada
The CCPS is designed as a multi-center, longitudinal, observational study that will collect clinical and biological data and specimens from children with a CPS and their relatives. The investigators plan to:
- Establish and maintain a framework for recruitment, participation, and surveillance of children with cancer predisposition syndromes (CPS) in clinical and translational research studies;
- Define the natural history of disease in children with CPS; and
- Evaluate the clinical impact and effectiveness of standard and emerging tumor surveillance strategies.
The study will enroll approximately 350 Children and 700 Relatives per year. The investigators plan to collect demographic and diagnostic data at enrollment. Longitudinal follow-up will be performed at least annually.
The CCPS includes the establishment of a biorepository, with a hub and spoke structure, with a central repository at Emory University/Children's Healthcare of Atlanta for prospective collection of some tissues, linked to local biorepositories at participating institutions. Information about inventory of tumor specimens already banked locally will be available in the database, along with reference to existing genomic studies of the tumor, such that investigators may identify and request such tissue or data for specific studies, subject to approval of the CCPS Scientific Committee.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Christopher Porter, MD
- Número de teléfono: 4047274881
- Correo electrónico: chris.porter@emory.edu
Ubicaciones de estudio
-
-
Ontario
-
Toronto, Ontario, Canadá
- Reclutamiento
- Hospital for Sick Children
-
Contacto:
- Anita Villani, MD
- Correo electrónico: anita.villani@sickkids.ca
-
-
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Reclutamiento
- Children's Healthcare of Atlanta (CHOA)
-
Contacto:
- Christopher Porter, MD
- Número de teléfono: 404-727-4881
- Correo electrónico: chris.porter@emory.edu
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Reclutamiento
- Dana Farber Cancer Institute
-
Contacto:
- Lisa Diller, MD
- Correo electrónico: lisa_diller@dfci.harvard.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Reclutamiento
- Children's Hospital of Philadelphia
-
Contacto:
- Suzanne MacFarland, MD
- Correo electrónico: macfarlands@chop.edu
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38105-3678
- Reclutamiento
- St. Jude Children's Research Hospital
-
Contacto:
- Kim Nichols, MD
- Correo electrónico: kim.nichols@stjude.org
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- Baylor College of Medicine
-
Contacto:
- Surya Rednam, MD
- Correo electrónico: sprednam@texaschildrens.org
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84113
- Reclutamiento
- Primary Children's Hospital
-
Contacto:
- Luke Maese, MD
- Correo electrónico: luke.maese@hsci.utah.edu
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
The Primary Subjects of this study are children (age 0-21) with a CPS. Members of their Primary Family Unit will also be recruited for this study, including CPS-Affected Parents, Unaffected Parents and Siblings. Other adult family members (with documented or obligate CPS) are also eligible to enroll as Affected Family Members.
Descripción
Inclusion Criteria:
Primary Subjects must meet all of the below criteria to be eligible for enrollment:
-
Be less than 21 years of age at the time of enrollment
-
Have a diagnosis of a specific CPS, whether they have had cancer or not
- Based on clinical laboratory testing demonstrating a Pathogenic or Likely Pathogenic germline variant and/or
- Based on well-established clinical diagnostic criteria and/or
- Based on high clinical suspicion of a specific CPS with clinical laboratory testing demonstrating a variant of uncertain significance (VUS)
Affected Parents must meet all of the following criteria to be eligible for enrollment:
- Be the biologic parent of a Primary Subject and
- Carry a diagnosis (or obligate diagnosis) of the familial CPS
Adult Affected Siblings must meet all of the following criteria to be eligible for enrollment:
- Be the biologic sibling of a Primary Subject and
- Carry a diagnosis (or obligate diagnosis) of the familial CPS
Unaffected Parents and Siblings must meet all of the following criteria to be eligible for enrollment
- Be the biologic parent or sibling of a Primary Subject and
- Not carry a diagnosis (or obligate diagnosis) of the familial CPS
Affected Family Members must meet all of the following criteria to be eligible for enrollment:
1. Carry a diagnosis of (or obligate diagnosis of) the familial CPS. Documentation is requested but not required.
More than one child from a Primary Family Unit may be a Primary Subject. An Unaffected Sibling may be reclassified as a Primary Subject if diagnosed with a CPS during childhood.
Exclusion Criteria:
- Individuals with a strong personal or family history of cancer without a genetic or clinical diagnosis of a specific CPS are not eligible for enrollment.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Primary Subjects
Children (age 0-21) with a cancer predisposition syndromes (CPS). |
This prospective registry and biorepository will collect clinical data and specimens for research in childhood cancer predisposition. |
|
Relatives of Children with CPS
Members of their Primary Family Unit will also be recruited for this study, including CPS-Affected Parents, Unaffected Parents and Siblings. Other adult family members (with documented or obligate CPS) are also eligible to enroll as Affected Family Members. |
This prospective registry and biorepository will collect clinical data and specimens for research in childhood cancer predisposition. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Establish and maintain a framework for recruitment, participation, and surveillance of children with cancer predisposition syndromes (CPS) in clinical and translational research studies.
Periodo de tiempo: Up to 10 years
|
This multicenter registry and biorepository will be developed with the purpose of studying individuals at high risk for childhood cancer to improve care and outcomes for pediatric patients with cancer and those with cancer predisposition syndromes (CPS). |
Up to 10 years
|
|
Define the natural history of disease in children with CPS.
Periodo de tiempo: Up to 10 years
|
To define the natural history of disease in children with CPS. |
Up to 10 years
|
|
Evaluate the clinical impact and effectiveness of standard and emerging tumor surveillance strategies.
Periodo de tiempo: Up to 10 years
|
Evaluate the clinical impact and effectiveness of standard and emerging tumor surveillance strategies to improve care and outcomes for pediatric patients with cancer and those with cancer predisposition syndromes (CPS). |
Up to 10 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Christopher Porter, MD, Emory University
- Investigador principal: Anita Villani, MD, The Hospital for Sick Children
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias
- Organización y administración
- Administración de Servicios de Salud
- Calidad, acceso y evaluación de la atención médica
- Técnicas de investigación
- Métodos epidemiológicos
- Recopilación de datos
- Mecanismos de evaluación de atención médica
- Calidad de la atención médica
- Salud pública
- Medio ambiente y salud pública
- Archivos
- Registros
Otros números de identificación del estudio
- STUDY00000109
- C3P-001 (Otro identificador: Consortium for Childhood Cancer Predisposition)
- 2020P002450 (Otro identificador: Emory IRB)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
De-identified, individual participant data reported in publications
Marco de tiempo para compartir IPD
Beginning 3 months and ending 5 years following article publication.
Criterios de acceso compartido de IPD
- Researchers who provide a methodologically sound proposal, to achieve the aims in the approved proposal
- Proposals should be directed to chris.porter@emory.edu. Requests will be reviewed by the study committee. Access to data will require a data access agreement.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- CIF
- CÓDIGO_ANALÍTICO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .